An overview of thrombopoietin: with a historical perspective.
A physiologically relevant thrombopoietin (TPO) must be a humoral regulator with lineage specificity for megakaryocytes and their precursors. It should be capable of stimulating platelet production in normal animals, and elevated levels of TPO should be detectable in the plasma following acute, severe thrombocytopenia. Acute thrombocytopenia provides a model system that is likely to predict the effects of TPO, since many of the effects on megakaryocytes and platelets observed after induction of acute thrombocytopenia would be mediated by TPO. Important questions remain to be answered. Do the currently available data for the c-Mpl ligand explain previously published data that describe elevated levels of Meg-CSF in the circulation following production of bone marrow aplasia? Does the c-Mpl ligand account for all of the megakaryocyte stimulatory factors that have been described? Is there another factor that accounts for at least some of the acute alterations in megakaryocytopoiesis that occur immediately following a decrease in platelet levels?
Levin
J
J
Department of Laboratory Medicine, University of California School of Medicine, San Francisco, USA.
D000208:Acute Disease; D000818:Animals; D002452:Cell Count; D049673:History, 20th Century; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051379:Mice; D010976:Platelet Count; D011971:Receptors, Immunologic / Q000266:history / Q000502:physiology*; D013921:Thrombocytopenia / Q000473:pathology; D013926:Thrombopoietin / Q000266:history / Q000494:pharmacology / Q000502:physiology*
D011971:Receptors, Immunologic; D013926:Thrombopoietin